Document is current
Any future updates will be listed below
-
Authors
Kellermann, Vanessa
Sengun Filiz, Ece
Said, Olena
Bentley, Jessica
Khor, Joel W.T.
Simic, Mima
Nicholls, Dasha
Treasure, Janet
Schmidt, Ulrike
Himmerich, Hubertus
Lawrence, Vanessa
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (NIHR130780)
- License Information
-
More Information
Article History
Received: 27 June 2024
Accepted: 10 September 2024
First Online: 27 September 2024
Declarations
:
: This study was approved by the Health and Social Care Research Ethics Committee B (Reference 22/NI/0010) and by the Health Research Authority (HRA) on the 11th of April 2022. Human Ethics and Consent to Participate declarations: All participants provided written consent to participate before data collection.
: All participants consented to publish data from interviews conducted. No identifiable information is included in the manuscript.
: HH is the chief investigator for an NIHR HTA-funded feasibility study testing olanzapine in young patients with anorexia nervosa (AN) and the principal investigator of a COMPASS Pathways-funded and -sponsored proof-of-concept study testing psilocybin in AN.
